

# PALL CORP (PLL)

## 10-Q

Quarterly report pursuant to sections 13 or 15(d)

Filed on 12/09/2011

Filed Period 10/31/2011

THOMSON REUTERS ACCELUS™



THOMSON REUTERS

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 10-Q**

Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

**For the quarterly period ended October 31, 2011**

or

Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

**Commission File Number: 001-04311**

**PALL CORPORATION**

(Exact name of registrant as specified in its charter)

**New York**

(State or other jurisdiction of  
incorporation or organization)

**11-1541330**

(I.R.S. Employer  
Identification No.)

**25 Harbor Park Drive, Port Washington, NY**

(Address of principal executive offices)

**11050**

(Zip Code)

**(516) 484-5400**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of shares of the registrant's common stock outstanding as of December 1, 2011 was 115,411,001.

---

## Table of Contents

|  | <b>Page No.</b> |
|--|-----------------|
| <b>PART I. FINANCIAL INFORMATION</b>   |                 |
| Item 1. Financial Statements (Unaudited).  |                 |
| Condensed Consolidated Balance Sheets as of October 31, 2011 and July 31, 2011.                                      | 3               |
| Condensed Consolidated Statements of Earnings for the three months ended<br>October 31, 2011 and October 31, 2010.   | 4               |
| Condensed Consolidated Statements of Cash Flows for the three months ended<br>October 31, 2011 and October 31, 2010. | 5               |
| Notes to Condensed Consolidated Financial Statements.  | 6               |
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.                       | 18              |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk.  | 27              |
| Item 4. Controls and Procedures.   | 27              |
| <b>PART II. OTHER INFORMATION</b>  |                 |
| Item 1. Legal Proceedings.   | 28              |
| Item 1A. Risk Factors.   | 28              |
| Item 6. Exhibits.  | 28              |
| <b>SIGNATURES</b>  |                 |

**PART I. FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS.**

**PALL CORPORATION AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(In thousands, except per share data)  
(Unaudited)

|  | <u>Oct. 31, 2011</u> | <u>July 31, 2011</u> |
|--|----------------------|----------------------|
| <b>ASSETS</b>                                    |                      |                      |
| Current assets:                                  |                      |                      |
| Cash and cash equivalents                        | \$ 475,394           | \$ 557,766           |
| Accounts receivable                              | 638,062              | 646,769              |
| Inventories                                      | 456,664              | 444,842              |
| Prepaid expenses                                 | 49,752               | 39,322               |
| Other current assets                             | <u>148,838</u>       | <u>120,509</u>       |
| Total current assets                             | 1,768,710            | 1,809,208            |
| Property, plant and equipment                    | 824,519              | 794,599              |
| Goodwill   | 299,030              | 290,606              |
| Intangible assets                                | 77,341               | 61,735               |
| Other non-current assets                         | 263,373              | 276,268              |
| Total assets                                     | <u>\$ 3,232,973</u>  | <u>\$ 3,232,416</u>  |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>      |                      |                      |
| Current liabilities:                             |                      |                      |
| Notes payable                                    | \$ 144,949           | \$ 214,957           |
| Accounts payable and other current liabilities   | 532,598              | 519,883              |
| Income taxes payable                             | 25,326               | 34,531               |
| Current portion of long-term debt                | 511                  | 511                  |
| Dividends payable                                | <u>20,149</u>        | <u>20,125</u>        |
| Total current liabilities                        | 723,533              | 790,007              |
| Long-term debt, net of current portion           | 494,771              | 491,954              |
| Income taxes payable – non-current               | 180,446              | 175,040              |
| Deferred taxes and other non-current liabilities | <u>299,173</u>       | <u>285,594</u>       |
| Total liabilities                                | 1,697,923            | 1,742,595            |
| Stockholders' equity:                            |                      |                      |
| Common stock, par value \$.10 per share          | 12,796               | 12,796               |
| Capital in excess of par value                   | 253,877              | 246,665              |
| Retained earnings                                | 1,669,244            | 1,619,051            |
| Treasury stock, at cost                          | (469,965)            | (483,705)            |
| Stock option loans                               | –                    | (133)                |
| Accumulated other comprehensive income/(loss):   |                      |                      |
| Foreign currency translation                     | 183,346              | 207,478              |
| Pension liability adjustment                     | (117,600)            | (121,831)            |
| Unrealized investment gains                      | <u>3,352</u>         | <u>9,500</u>         |
|  | 69,098               | 95,147               |
| Total stockholders' equity                       | 1,535,050            | 1,489,821            |
| Total liabilities and stockholders' equity       | <u>\$ 3,232,973</u>  | <u>\$ 3,232,416</u>  |

See accompanying notes to condensed consolidated financial statements.



**PALL CORPORATION AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS**  
(In thousands, except per share data)  
(Unaudited)

|  | <b>Three Months Ended</b> |                      |
|--|---------------------------|----------------------|
|  | <b>Oct. 31, 2011</b>      | <b>Oct. 31, 2010</b> |
| Net sales                                    | \$ 705,641                | \$ 605,477           |
| Cost of sales                                | 349,385                   | 296,804              |
| Gross profit                                 | 356,256                   | 308,673              |
| Selling, general and administrative expenses | 213,896                   | 182,298              |
| Research and development                     | 20,938                    | 20,169               |
| Restructuring and other charges, net         | 22,984                    | 1,409                |
| Interest expense, net                        | 5,945                     | 7,294                |
| Earnings before income taxes                 | 92,493                    | 97,503               |
| Provision for income taxes                   | 23,038                    | 26,094               |
| Net earnings                                 | <u>\$ 69,455</u>          | <u>\$ 71,409</u>     |
| Earnings per share:                          |                           |                      |
| Basic  | \$ 0.60                   | \$ 0.61              |
| Diluted                                      | \$ 0.59                   | \$ 0.61              |
| Dividends declared per share                 | \$ 0.175                  | \$ 0.160             |
| Average shares outstanding:                  |                           |                      |
| Basic  | 115,824                   | 116,292              |
| Diluted                                      | 117,224                   | 117,821              |

See accompanying notes to condensed consolidated financial statements.

**PALL CORPORATION AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(In thousands)  
(Unaudited)

|  | <b>Three Months Ended</b> |                      |
|--|---------------------------|----------------------|
|  | <b>Oct. 31, 2011</b>      | <b>Oct. 31, 2010</b> |
| <b>Operating activities:</b>                                   |                           |                      |
| Net cash provided by operating activities                      | \$ 78,356                 | \$ 58,686            |
| <b>Investing activities:</b>                                   |                           |                      |
| Acquisition of business  | (28,000)                  | –                    |
| Proceeds from sale of assets                                   | 19,837                    | 300                  |
| Capital expenditures   | (56,649)                  | (25,358)             |
| Proceeds from sale of retirement benefit assets                | 9,675                     | 20,259               |
| Purchases of retirement benefit assets                         | (12,241)                  | (31,253)             |
| Other  | (1,798)                   | (1,336)              |
| Net cash used by investing activities                          | (69,176)                  | (37,388)             |
| <b>Financing activities:</b>                                   |                           |                      |
| Notes payable  | (70,008)                  | 3,669                |
| Long-term borrowings   | 52                        | 35,021               |
| Repayments of long-term debt                                   | (141)                     | (55,516)             |
| Dividends paid   | (20,125)                  | (36,976)             |
| Net proceeds from stock plans                                  | 9,759                     | 13,989               |
| Purchase of treasury stock                                     | –                         | (25,000)             |
| Excess tax benefits from stock-based compensation arrangements | 532                       | 1,288                |
| Net cash used by financing activities                          | (79,931)                  | (63,525)             |
| Cash flow for period   | (70,751)                  | (42,227)             |
| Cash and cash equivalents at beginning of year                 | 557,766                   | 498,563              |
| Effect of exchange rate changes on cash and cash equivalents   | (11,621)                  | 23,041               |
| Cash and cash equivalents at end of period                     | \$ 475,394                | \$ 479,377           |
| <b>Supplemental disclosures:</b>                               |                           |                      |
| Interest paid  | \$ 1,304                  | \$ 2,305             |
| Income taxes paid (net of refunds)                             | 29,379                    | 34,049               |

See accompanying notes to condensed consolidated financial statements.

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

**NOTE 1 - BASIS OF PRESENTATION**

The condensed consolidated financial information of Pall Corporation and its subsidiaries (hereinafter collectively called the "Company") included herein is unaudited. Such information reflects all adjustments of a normal recurring nature, which are, in the opinion of Company management, necessary to present fairly the Company's consolidated financial position, results of operations and cash flows as of the dates and for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes set forth in the Company's Annual Report on Form 10-K for the fiscal year ended July 31, 2011 ("2011 Form 10-K"). Certain prior year amounts have been reclassified to conform to the current year presentation.

**NOTE 2 - BALANCE SHEET DETAILS**

The following tables provide details of selected balance sheet items:

|  | <b>Oct. 31, 2011</b> | <b>July 31, 2011</b> |
|--|----------------------|----------------------|
| <b>Accounts receivable:</b>            |                      |                      |
| Billed                                 | \$ 542,912           | \$ 553,500           |
| Unbilled                               | 105,179              | 101,652              |
| Total                                  | 648,091              | 655,152              |
| Less: Allowances for doubtful accounts | (10,029)             | (8,383)              |
|  | <u>\$ 638,062</u>    | <u>\$ 646,769</u>    |

Unbilled receivables principally relate to long-term contracts recorded under the percentage-of-completion method of accounting.

|                              | <b>Oct. 31, 2011</b> | <b>July 31, 2011</b> |
|------------------------------|----------------------|----------------------|
| <b>Inventories:</b>          |                      |                      |
| Raw materials and components | \$ 117,344           | \$ 102,745           |
| Work-in-process              | 88,018               | 96,601               |
| Finished goods               | 251,302              | 245,496              |
|                              | <u>\$ 456,664</u>    | <u>\$ 444,842</u>    |

|   | <b>Oct. 31, 2011</b> | <b>July 31, 2011</b> |
|---|----------------------|----------------------|
| <b>Property, plant and equipment:</b>           |                      |                      |
| Property, plant and equipment                   | \$ 1,745,385         | \$ 1,705,559         |
| Less: Accumulated depreciation and amortization | (920,866)            | (910,960)            |
|   | <u>\$ 824,519</u>    | <u>\$ 794,599</u>    |

**NOTE 3 - GOODWILL AND INTANGIBLE ASSETS**

The following table presents goodwill, allocated by reportable segment.

|               | <b>Oct. 31, 2011</b> | <b>July 31, 2011</b> |
|---------------|----------------------|----------------------|
| Life Sciences | \$ 134,193           | \$ 131,852           |
| Industrial    | 164,837              | 158,754              |
|               | <u>\$ 299,030</u>    | <u>\$ 290,606</u>    |



**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

Intangible assets, net, consist of the following:

|                                   | <b>Oct. 31, 2011</b> |                     |                 |
|-----------------------------------|----------------------|---------------------|-----------------|
|                                   | <b>Accumulated</b>   |                     |                 |
|                                   | <b>Gross</b>         | <b>Amortization</b> | <b>Net</b>      |
| Patents and unpatented technology | \$102,404            | \$ 67,259           | \$35,145        |
| Customer-related intangibles      | 45,124               | 7,839               | 37,285          |
| Trademarks                        | 7,008                | 4,820               | 2,188           |
| Other                             | 5,325                | 2,602               | 2,723           |
|                                   | <u>\$159,861</u>     | <u>\$ 82,520</u>    | <u>\$77,341</u> |

  

|                                   | <b>July 31, 2011</b> |                     |                 |
|-----------------------------------|----------------------|---------------------|-----------------|
|                                   | <b>Accumulated</b>   |                     |                 |
|                                   | <b>Gross</b>         | <b>Amortization</b> | <b>Net</b>      |
| Patents and unpatented technology | \$102,372            | \$ 64,921           | \$37,451        |
| Customer-related intangibles      | 26,478               | 6,598               | 19,880          |
| Trademarks                        | 6,802                | 4,684               | 2,118           |
| Other                             | 4,685                | 2,399               | 2,286           |
|                                   | <u>\$140,337</u>     | <u>\$ 78,602</u>    | <u>\$61,735</u> |

The changes in both goodwill and intangible assets in the first quarter of fiscal year 2012 relate to an acquisition in Brazil. In connection with the acquisition, the Company recorded the fair value of the intangible assets acquired (approximately \$20,000, with the majority recorded as customer-related intangibles), which were valued using the income approach. The amount of goodwill recorded in connection with this acquisition was approximately \$10,000. In addition, the carrying amounts were also impacted by changes in foreign exchange rates used to translate the goodwill and intangible assets contained in the financial statements of foreign subsidiaries using the rates at each respective balance sheet date.

Amortization expense for intangible assets for the three months ended October 31, 2011 and October 31, 2010 was \$4,192 and \$3,196, respectively. Amortization expense is estimated to be approximately \$13,061 for the remainder of fiscal year 2012, \$11,734 in fiscal year 2013, \$9,769 in fiscal year 2014, \$8,067 in fiscal year 2015, \$6,964 in fiscal year 2016 and \$6,895 in fiscal year 2017.

**NOTE 4 - TREASURY STOCK**

On October 16, 2008, the board authorized an expenditure of \$350,000 to repurchase shares. On September 26, 2011, the board authorized an additional \$250,000. The Company's shares may be purchased over time, as market and business conditions warrant. There is no time restriction on these authorizations. There were no share repurchases during the three months ended October 31, 2011. As of October 31, 2011, \$453,037 remains to be expended under the current board repurchase authorizations. Repurchased shares are held in treasury for use in connection with the Company's stock plans and for general corporate purposes.

During the three months ended October 31, 2011, 381 shares were issued under the Company's stock-based compensation plans. At October 31, 2011, the Company held 12,582 treasury shares.

**NOTE 5 - CONTINGENCIES AND COMMITMENTS**

With respect to the matters described in Note 14, Contingencies and Commitments, to the Company's consolidated financial statements included in the 2011 Form 10-K, under the heading Federal Securities Class Actions, Shareholder Derivative Lawsuits and Other Proceedings, the Company has assessed the ultimate resolution of these matters and has reflected appropriate contingent liabilities and related insurance recoveries of an equal amount in the condensed consolidated financial statements as of October 31, 2011 and July 31, 2011.

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

The Company and its subsidiaries are subject to certain other legal actions that arise in the normal course of business. Other than those legal proceedings and claims discussed below and in the 2011 Form 10-K, the Company did not have any current other legal proceedings and claims that would individually or in the aggregate have a reasonably possible materially adverse affect on its financial condition or operating results. However, the results of legal proceedings cannot be predicted with certainty. If the Company failed to prevail in several of these legal matters in the same reporting period, the operating results of a particular reporting period could be materially adversely affected.

**Environmental Matters:**

The Company's condensed consolidated balance sheet at October 31, 2011 includes liabilities for environmental matters of approximately \$14,472, which relate primarily to the environmental proceedings discussed in the 2011 Form 10-K. In the opinion of management, the Company is in substantial compliance with applicable environmental laws and its current accruals for environmental remediation are adequate. However, as regulatory standards under environmental laws are becoming increasingly stringent, there can be no assurance that future developments, additional information and experience gained will not cause the Company to incur material environmental liabilities or costs beyond those accrued in its condensed consolidated financial statements.

**NOTE 6 - RESTRUCTURING AND OTHER CHARGES, NET**

The following tables summarize the restructuring and other charges ("ROTC") recorded for the three months ended October 31, 2011 and October 31, 2010:

|  | <b>Three Months Ended Oct. 31, 2011</b> |                                       |                  |
|--|---|---------------------------------------|------------------|
|  | <b>Restructuring</b>                    | <b>Other<br/>(Gains)/<br/>Charges</b> | <b>Total</b>     |
|  | (1)                                     | (2)                                   |                  |
| Termination benefits and other employment contract obligations       | \$ 25,408                               | \$ 7,970                              | \$ 33,378        |
| Gain on sale of assets   | (1,515)                                 | (9,196)                               | (10,711)         |
| Professional fees and other costs, net of receipt of insurance claim | 775                                     | (412)                                 | 363              |
| Reversal of excess restructuring reserves                            | (46)                                    | --                                    | (46)             |
|  | <u>\$ 24,622</u>                        | <u>\$ (1,638)</u>                     | <u>\$ 22,984</u> |
| Change in cash   | \$ 24,622                               | \$ (3,806)                            | \$ 20,816        |
| Non-cash(a)  | -                                       | 2,168                                 | 2,168            |
|  | <u>\$ 24,622</u>                        | <u>\$ (1,638)</u>                     | <u>\$ 22,984</u> |
|  | <b>Three Months Ended Oct. 31, 2010</b> |                                       |                  |
|  | <b>Restructuring</b>                    | <b>Other<br/>Charges</b>              | <b>Total</b>     |
|  | (1)                                     | (2)                                   |                  |
| Professional fees and other costs                                    | \$ 1,011                                | \$ 404                                | \$ 1,415         |
| Reversal of excess restructuring reserves                            | (6)                                     | -                                     | (6)              |
|  | <u>\$ 1,005</u>                         | <u>\$ 404</u>                         | <u>\$ 1,409</u>  |
| Change in cash   | \$ 1,005                                | \$ 404                                | \$ 1,409         |
| Non-cash   | -                                       | -                                     | -                |
|  | <u>\$ 1,005</u>                         | <u>\$ 404</u>                         | <u>\$ 1,409</u>  |

(a) Reflects \$2,168 of non-cash stock based compensation costs.

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

(1) Restructuring:

Restructuring charges reflect the expenses incurred in connection with the Company's cost reduction initiatives. Severance costs recorded in the three months ended October 31, 2011 primarily relate to global restructuring activities in the Industrial segment. The most significant restructuring activities include:

- the realignment of sales and marketing management of certain of the Company's markets,
- the reorganization of the global management structure that supports the Company's systems product line, and
- shifting resources from mature country markets to emerging regions.

Restructuring also includes a gain of \$1,515 on the divestiture of a certain non-strategic asset group.

(2) Other Charges:

Employment contract obligations and other severance benefits:

In the three months ended October 31, 2011, the Company recorded charges related to certain employment contract obligations.

Gain on sale of assets:

In the three months ended October 31, 2011, the Company recorded a gain of \$9,196 on the sale of its investment in Satair A/S.

Professional fees and other costs:

In the three months ended October 31, 2011 and October 31, 2010, the Company recorded legal and other professional fees related to the Federal Securities Class Actions, Shareholder Derivative Lawsuits and Other Proceedings (see Note 5, Contingencies and Commitments) which pertain to matters that had been under audit committee inquiry as discussed in Note 2, Audit Committee Inquiry and Restatement, to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended July 31, 2007 ("2007 Form 10-K"). The receipt of insurance claim payments more than offset such costs in the three months ended October 31, 2011.

The following table summarizes the activity related to restructuring liabilities that were recorded in the three months ended October 31, 2011 and in fiscal years 2011, 2010 and 2009.

|                          | <u>Severance</u> | <u>Other</u>  | <u>Total</u>     |
|--------------------------|------------------|---------------|------------------|
| <b>2012</b>              |                  |               |                  |
| Original charge          | \$ 25,408        | \$ 775        | \$ 26,183        |
| Utilized                 | (1,981)          | (546)         | (2,527)          |
| Translation              | 66               | 3             | 69               |
| Balance at Oct. 31, 2011 | <u>\$ 23,493</u> | <u>\$ 232</u> | <u>\$ 23,725</u> |
| <b>2011</b>              |                  |               |                  |
| Original charge          | \$ 4,863         | \$ 5,507      | \$ 10,370        |
| Utilized                 | (1,817)          | (5,225)       | (7,042)          |
| Translation              | 272              | 68            | 340              |
| Balance at Jul. 31, 2011 | \$ 3,318         | \$ 350        | \$ 3,668         |
| Utilized                 | (2,197)          | (350)         | (2,547)          |
| Translation              | (42)             | -             | (42)             |
| Balance at Oct. 31, 2011 | <u>\$ 1,079</u>  | <u>\$ -</u>   | <u>\$ 1,079</u>  |

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

|                             | <u>Severance</u> | <u>Other</u> | <u>Total</u>    |
|-----------------------------|------------------|--------------|-----------------|
| <b>2010</b>                 |                  |              |                 |
| Original charge (a)         | \$ 6,034         | \$ 5,581     | \$ 11,615       |
| Utilized                    | (2,031)          | (5,441)      | (7,472)         |
| Translation                 | 1                | (9)          | (8)             |
| Balance at Jul. 31, 2010    | \$ 4,004         | \$ 131       | \$ 4,135        |
| Utilized                    | (1,356)          | (135)        | (1,491)         |
| Translation                 | 2                | 4            | 6               |
| Balance at Jul. 31, 2011    | \$ 2,650         | \$ –         | \$ 2,650        |
| Utilized                    | (921)            | –            | (921)           |
| Translation                 | –                | –            | –               |
| Balance at Oct. 31, 2011    | <u>\$ 1,729</u>  | <u>\$ –</u>  | <u>\$ 1,729</u> |
| <b>2009</b>                 |                  |              |                 |
| Original charge             | \$ 18,938        | \$ 4,734     | \$ 23,672       |
| Utilized                    | (12,757)         | (4,133)      | (16,890)        |
| Translation                 | 412              | 20           | 432             |
| Balance at Jul. 31, 2009    | 6,593            | 621          | 7,214           |
| Utilized                    | (4,902)          | (588)        | (5,490)         |
| Reversal of excess reserves | (143)            | –            | (143)           |
| Translation                 | (86)             | (27)         | (113)           |
| Balance at Jul. 31, 2010    | \$ 1,462         | \$ 6         | \$ 1,468        |
| Utilized                    | (845)            | (6)          | (851)           |
| Reversal of excess reserves | (6)              | –            | (6)             |
| Translation                 | 120              | –            | 120             |
| Balance at Jul. 31, 2011    | \$ 731           | \$ –         | \$ 731          |
| Utilized                    | (121)            | –            | (121)           |
| Reversal of excess reserves | (46)             | –            | (46)            |
| Translation                 | (13)             | –            | (13)            |
| Balance at Oct. 31, 2011    | <u>\$ 551</u>    | <u>\$ –</u>  | <u>\$ 551</u>   |

(a) Excludes stock-based compensation expense of \$603

**NOTE 7 – INCOME TAXES**

The Company's effective tax rate for the three months ended October 31, 2011 and October 31, 2010 was 24.9% and 26.8%, respectively. For the three months ended October 31, 2011 and October 31, 2010, the effective tax rate varied from the U.S. federal statutory rate primarily due to the benefits of foreign operations.

At October 31, 2011 and July 31, 2011, the Company had gross unrecognized income tax benefits of \$193,623 and \$188,380, respectively. During the three months ended October 31, 2011, the amount of gross unrecognized tax benefits increased by \$5,243, primarily due to tax positions taken during the current period. As of October 31, 2011, the amount of net unrecognized income tax benefits that, if recognized, would impact the effective tax rate was \$131,890.

At October 31, 2011 and July 31, 2011, the Company had liabilities of \$30,778 and \$29,652, respectively, for potential payment of interest and penalties.

Due to the potential resolution of tax examinations and the expiration of various statutes of limitation, the Company believes that it is reasonably possible that the gross amount of unrecognized tax benefits may decrease within the next twelve months by a range of zero to \$6,782.

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

**NOTE 8 - COMPONENTS OF NET PERIODIC PENSION COST**

The Company provides substantially all domestic and foreign employees with retirement benefits. Net periodic pension benefit cost for the Company's defined benefit pension plans includes the following components:

|  | <b>Three Months Ended</b> |                          |                          |                          |
|--|---------------------------|--------------------------|--------------------------|--------------------------|
|  | <b>U.S. Plans</b>         |                          | <b>Foreign Plans</b>     |                          |
|  | <b>Oct. 31,<br/>2011</b>  | <b>Oct. 31,<br/>2010</b> | <b>Oct. 31,<br/>2011</b> | <b>Oct. 31,<br/>2010</b> |
| Service cost                             | \$ 2,231                  | \$ 2,015                 | \$ 1,210                 | \$ 1,287                 |
| Interest cost                            | 3,596                     | 3,032                    | 4,635                    | 4,516                    |
| Expected return on plan assets           | (2,303)                   | (2,203)                  | (3,964)                  | (3,512)                  |
| Amortization of prior service cost       | 657                       | 456                      | (33)                     | 71                       |
| Recognized actuarial loss                | 3,454                     | 967                      | 1,335                    | 1,399                    |
| Gain due to curtailments and settlements | -                         | -                        | -                        | (23)                     |
| <b>Net periodic benefit cost</b>         | <b>\$ 7,635</b>           | <b>\$ 4,267</b>          | <b>\$ 3,183</b>          | <b>\$ 3,738</b>          |

**NOTE 9 - STOCK-BASED PAYMENT**

The Company currently has four stock-based employee and director compensation award types (Restricted Stock Unit, Stock Option Plans, Management Stock Purchase Plan ("MSPP"), and Employee Stock Purchase Plan ("ESPP")), which are more fully described in Note 15, Common Stock, to the consolidated financial statements included in the 2011 Form 10-K.

The detailed components of stock-based compensation expense recorded in the condensed consolidated statements of earnings for the three months ended October 31, 2011 and October 31, 2010 are reflected in the table below.

|                        | <b>Three Months Ended</b> |                          |
|------------------------|---------------------------|--------------------------|
|                        | <b>Oct. 31,<br/>2011</b>  | <b>Oct. 31,<br/>2010</b> |
| Restricted stock units | \$ 4,786                  | \$ 2,394                 |
| Stock options          | 1,882                     | 1,010                    |
| ESPP                   | 1,203                     | 988                      |
| MSPP                   | 999                       | 1,024                    |
| <b>Total</b>           | <b>\$ 8,870</b>           | <b>\$ 5,416</b>          |

**NOTE 10 - EARNINGS PER SHARE**

The condensed consolidated statements of earnings present basic and diluted earnings per share. Basic earnings per share is determined by dividing income available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share considers the potential effect of dilution on basic earnings per share assuming potentially dilutive shares that meet certain criteria, such as those issuable upon exercise of stock options, were outstanding. The treasury stock method reduces the dilutive effect of potentially dilutive securities as it assumes that cash proceeds (from the issuance of potentially dilutive securities) are used to buy back shares at the average share price during the period. Employee stock options and restricted stock units aggregating 984 and 922 shares were not included in the computation of diluted shares for the three months ended October 31, 2011 and October 31, 2010, respectively, because their effect would have been antidilutive. The following is a reconciliation between basic shares outstanding and diluted shares outstanding:

|                                   | <b>Three Months Ended</b> |                      |
|-----------------------------------|---------------------------|----------------------|
|                                   | <b>Oct. 31, 2011</b>      | <b>Oct. 31, 2010</b> |
| Basic shares outstanding          | 115,824                   | 116,292              |
| Effect of stock plans             | 1,400                     | 1,529                |
| <b>Diluted shares outstanding</b> | <b>117,224</b>            | <b>117,821</b>       |

---

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

NOTE 11 - FAIR VALUE MEASUREMENTS

The Company records certain of its financial assets and liabilities at fair value, which is the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date.

The current authoritative guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). Authoritative guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

- Level 1: Use of observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: Use of inputs other than quoted prices included in Level 1, which are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.
- Level 3: Use of inputs that are unobservable.

The following table presents, for each of these hierarchy levels, the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of October 31, 2011:

|  | <b>Fair Value Measurements</b> |                |                |                |
|--|--------------------------------|----------------|----------------|----------------|
|  | <b>As of<br/>Oct. 31, 2011</b> | <b>Level 1</b> | <b>Level 2</b> | <b>Level 3</b> |
| <b>Financial assets carried at fair value</b>      |                                |                |                |                |
| Money market funds                                 | \$ 3,169                       | \$ 3,169       | \$ –           | \$ –           |
| Available-for-sale securities:                     |                                |                |                |                |
| Equity securities                                  | 986                            | 986            | –              | –              |
| Debt securities:                                   |                                |                |                |                |
| Corporate  | 31,332                         | –              | 31,332         | –              |
| U.S. Treasury                                      | 10,409                         | –              | 10,409         | –              |
| Federal agency                                     | 30,452                         | –              | 30,452         | –              |
| Mortgage-backed                                    | 6,236                          | –              | 6,236          | –              |
| Municipal government                               | 1,000                          | –              | 1,000          | –              |
| Derivative financial instruments:                  |                                |                |                |                |
| Foreign exchange forward contracts                 | 2,228                          | –              | 2,228          | –              |
| <b>Financial liabilities carried at fair value</b> |                                |                |                |                |
| Derivative financial instruments:                  |                                |                |                |                |
| Foreign exchange forward contracts                 | 3,426                          |                | 3,426          |                |

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

The following table presents, for each of these hierarchy levels, the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of July 31, 2011:

|  | Fair Value Measurement |          |         |
|--|------------------------|----------|---------|
|  | As of<br>Jul. 31, 2011 | Level 1  | Level 2 |
| <b>Financial assets carried at fair value</b>      |                        |          |         |
| Money market funds                                 | \$ 4,575               | \$ 4,575 | \$ —    |
| Available-for-sale securities:                     |                        |          |         |
| Equity securities                                  | 12,064                 | 12,064   | —       |
| Debt securities:                                   |                        |          |         |
| Corporate  | 32,020                 | —        | —       |
| U.S. Treasury                                      | 10,210                 | —        | —       |
| Federal agency                                     | 29,404                 | —        | —       |
| Mortgage-backed                                    | 6,356                  | —        | —       |
| Municipal government                               | 1,002                  | —        | —       |
| Derivative financial instruments:                  |                        |          |         |
| Foreign exchange forward contracts                 | 1,456                  | —        | —       |
| <b>Financial liabilities carried at fair value</b> |                        |          |         |
| Derivative financial instruments:                  |                        |          |         |
| Foreign exchange forward contracts                 | 478                    | —        | —       |

The Company's money market funds and equity securities are valued using quoted market prices and, as such, are classified within Level 1 of the fair value hierarchy.

The fair value of the Company's investments in debt securities are valued utilizing third party pricing services. The pricing services use inputs to determine fair value which are derived from observable market sources including reportable trades, benchmark curves, credit spreads, broker/dealer quotes, bids, offers, and other industry and economic events. These investments are included in Level 2 of the fair value hierarchy.

The fair values of the Company's foreign currency forward contracts are valued using pricing models, with all significant inputs derived from or corroborated by observable market data such as yield curves, currency spot and forward rates and currency volatilities. These investments are included in Level 2 of the fair value hierarchy.

In connection with the acquisition in the first quarter of fiscal year 2012, the Company recorded the fair value of the intangible assets acquired, which were valued using the income approach. The valuation employed level 3 inputs, as defined in the fair value hierarchy.

**NOTE 12 – INVESTMENT SECURITIES**

The following is a summary of the Company's available-for-sale investment securities by category which are classified within other non-current assets in the Company's condensed consolidated balance sheets. Contractual maturity dates of debt securities held by the trust at October 31, 2011 range from 2012 to 2044.



**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

|                         | Cost/<br>Amortized<br>Cost Basis | Fair Value       | Gross<br>Unrealized<br>Holding<br>Gains | Gross<br>Unrealized<br>Holding<br>Losses | Net<br>Unrealized<br>Holding<br>Gains/ |
|-------------------------|----------------------------------|------------------|---|--|--|
| <b>October 31, 2011</b> |                                  |                  |   |  |  |
| Equity securities       | \$ 986                           | \$ 986           | \$ -                                    | \$ -                                     | \$ -                                   |
| Debt securities:        |                                  |                  |   |  |  |
| Corporate               | 29,596                           | 31,332           | 1,822                                   | (86)                                     | 1,736                                  |
| U.S. Treasury           | 9,653                            | 10,409           | 756                                     | -  | 756                                    |
| Federal agency          | 28,966                           | 30,452           | 1,496                                   | (10)                                     | 1,486                                  |
| Mortgage-backed         | 6,212                            | 6,236            | 125                                     | (101)                                    | 24                                     |
| Municipal government    | 1,000                            | 1,000            | -                                       | -  | -                                      |
|                         | <u>\$ 76,413</u>                 | <u>\$ 80,415</u> | <u>\$ 4,199</u>                         | <u>\$ (197)</u>                          | <u>\$ 4,002</u>                        |

|                      |                  |                  |                  |                |                  |
|----------------------|------------------|------------------|------------------|----------------|------------------|
| <b>July 31, 2011</b> |                  |                  |                  |                |                  |
| Equity securities    | \$ 2,381         | \$ 12,064        | \$ 9,683         | \$ -           | \$ 9,683         |
| Debt securities:     |                  |                  |                  |                |                  |
| Corporate            | 30,239           | 32,020           | 1,814            | (33)           | 1,781            |
| U.S. Treasury        | 9,544            | 10,210           | 666              | -              | 666              |
| Federal agency       | 28,042           | 29,404           | 1,362            | -              | 1,362            |
| Mortgage-backed      | 6,242            | 6,356            | 144              | (30)           | 114              |
| Municipal government | 1,000            | 1,002            | 2                | -              | 2                |
|                      | <u>\$ 77,448</u> | <u>\$ 91,056</u> | <u>\$ 13,671</u> | <u>\$ (63)</u> | <u>\$ 13,608</u> |

The following table shows the gross unrealized losses and fair value of the Company's available-for-sale investments with unrealized losses aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position:

|                         | Less than 12 months |  | 12 months or greater |  | Total           |  |
|-------------------------|---------------------|--|----------------------|--|-----------------|--|
|                         | Fair<br>Value       | Gross<br>Unrealized<br>Holding<br>Losses | Fair<br>Value        | Gross<br>Unrealized<br>Holding<br>Losses | Fair<br>Value   | Gross<br>Unrealized<br>Holding<br>Losses |
| <b>October 31, 2011</b> |                     |  |                      |  |                 |  |
| Debt securities:        |                     |  |                      |  |                 |  |
| Mortgage-backed         | \$ 3,125            | \$ 101                                   | \$ -                 | \$ -                                     | \$ 3,125        | \$ 101                                   |
| Federal agency          | 1,109               | 10                                       | -                    | -  | 1,109           | 10                                       |
| Corporate               | 3,795               | 86                                       | -                    | -  | 3,795           | 86                                       |
|                         | <u>\$ 8,029</u>     | <u>\$ 197</u>                            | <u>\$ -</u>          | <u>\$ -</u>                              | <u>\$ 8,029</u> | <u>\$ 197</u>                            |

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

|                      | Less than 12 months |                                 | 12 months or greater |                                 | Total           |                                 |
|----------------------|---------------------|---------------------------------|----------------------|---------------------------------|-----------------|---------------------------------|
|                      | Fair Value          | Gross Unrealized Holding Losses | Fair Value           | Gross Unrealized Holding Losses | Fair Value      | Gross Unrealized Holding Losses |
| <b>July 31, 2011</b> |                     |                                 |                      |                                 |                 |                                 |
| Debt securities:     |                     |                                 |                      |                                 |                 |                                 |
| Mortgage-backed      | \$ 1,502            | \$ 30                           | \$ –                 | \$ –                            | \$ 1,502        | \$ 30                           |
| Corporate            | 1,985               | 33                              | –                    | –                               | 1,985           | 33                              |
|                      | <u>\$ 3,487</u>     | <u>\$ 63</u>                    | <u>\$ –</u>          | <u>\$ –</u>                     | <u>\$ 3,487</u> | <u>\$ 63</u>                    |

The following table shows the proceeds and gross gains and losses from the sale of available-for-sale investments for the three months ended October 31, 2011 and October 31, 2010:

|                                | Oct. 31, 2011 | Oct. 31, 2010 |
|--------------------------------|---------------|---------------|
| Proceeds from sales            | \$ 16,047     | \$ 3,542      |
| Realized gross gains on sales  | 9,363         | 180           |
| Realized gross losses on sales | 16            | –             |

**NOTE 13 - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES**

The Company manages certain financial exposures through a risk management program that includes the use of foreign exchange and interest rate derivative financial instruments. Derivatives are executed with counterparties with a minimum credit rating of "A" by Standard & Poors and Moody's Investor Services, in accordance with the Company's policies. The Company does not utilize derivative instruments for trading or speculative purposes.

Foreign Exchange Related:

a. Derivatives Not Designated as Hedging Instruments

The risk management objective of holding foreign exchange derivatives is to mitigate volatility to earnings and cash flows due to changes in foreign exchange rates. The Company and its subsidiaries conduct transactions in currencies other than their functional currencies. These transactions include non-functional intercompany and external sales as well as intercompany and external purchases. The Company uses foreign exchange forward contracts, matching the notional amounts and durations of the receivables and payables resulting from the aforementioned underlying foreign currency transactions, to mitigate the exposure to earnings and cash flows caused by the changes in fair value of these receivables and payables from fluctuating foreign exchange rates. The notional amount of foreign currency forward contracts entered into during the three months ended October 31, 2011 was \$882,544. The notional amount of foreign currency forward contracts outstanding as of October 31, 2011 was \$278,695.

b. Net Investment Hedges

The risk management objective of designating the Company's foreign currency loan as a hedge of a portion of its net investment in a wholly owned Japanese subsidiary is to mitigate the change in the fair value of the Company's net investment due to changes in foreign exchange rates. The Company uses a JPY loan outstanding to hedge its equity of the same amount in the Japanese wholly owned subsidiary. The hedge of net investment consists of a JPY 9 billion loan.

Interest Rate Related:

As of October 31, 2011, there are no existing interest rate related derivatives.

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

The fair values of the Company's derivative financial instruments included in the condensed consolidated balance sheets are presented as follows:

|  | Asset Derivatives      |                 | Liability Derivatives                  |                   |
|--|------------------------|-----------------|--|-------------------|
|  | Balance Sheet Location | Fair Value      | Balance Sheet Location                 | Fair Value        |
| <b>October 31, 2011</b>  |                        |                 |  |                   |
| <b>Derivatives designated as hedging instruments</b>               |                        |                 |  |                   |
| Not applicable (N/A)   |                        |                 |  |                   |
| <b>Derivatives not designated as hedging instruments</b>           |                        |                 |  |                   |
| Foreign exchange forward contracts                                 | Other current assets   | \$ 2,228        | Other current liabilities              | \$ 3,426          |
| <b>Total derivatives</b>   |                        | <u>\$ 2,228</u> |  | <u>\$ 3,426</u>   |
| <b>Nonderivative instruments designated as hedging instruments</b> |                        |                 |  |                   |
| Net investment hedge   |                        |                 | Long-term debt, net of current portion | <u>\$ 118,692</u> |
| <b>July 31, 2011</b>   |                        |                 |  |                   |
| <b>Derivatives designated as hedging instruments</b>               |                        |                 |  |                   |
| N/A  |                        |                 |  |                   |
| <b>Derivatives not designated as hedging instruments</b>           |                        |                 |  |                   |
| Foreign exchange forward contracts                                 | Other current assets   | \$ 1,456        | Other current liabilities              | \$ 478            |
| <b>Total derivatives</b>   |                        | <u>\$ 1,456</u> |  | <u>\$ 478</u>     |
| <b>Nonderivative instruments designated as hedging instruments</b> |                        |                 |  |                   |
| Net investment hedge   |                        |                 | Long-term debt, net of current portion | <u>\$ 115,803</u> |

For the three months ended October 31, 2011 and October 31, 2010, the Company had no derivative financial instruments outstanding that were designated as hedging instruments.

The amounts of the gains and losses related to the Company's derivative financial instruments not designated as hedging instruments for the three months ended October 31, 2011 and October 31, 2010 are presented as follows:

|  | Location of Gain or (Loss) Recognized in Earnings on Derivatives | Amount of Gain or (Loss) Recognized in Earnings on Derivatives |                   |
|--|--|--|-------------------|
|  |  | Three Months Ended   |                   |
|  |  | Oct. 31, 2011  | Oct. 31, 2010     |
| <b>Derivatives not designated as hedging relationships</b> |  |  |                   |
| Foreign exchange forward contracts                         | Selling, general and administrative expenses                     | <u>\$ 1,415</u>  | <u>\$ (2,335)</u> |

The amounts of the gains and losses related to the Company's nonderivative financial instruments designated as hedging instruments for the three months ended October 31, 2011 and October 31, 2010 are presented as follows:

| Amount of Gain or (Loss) Recognized in OCI on Derivatives (Effective Portion) | Location of Gain or (Loss) Reclassified from Accumulated OCI into Earnings (Effective Portion) | Amount of Gain or (Loss) Reclassified from Accumulated OCI into Earnings (Effective Portion) <sup>(a)</sup> |
|---|--|---|
|   |  |   |

|   | Three Months<br>Ended<br>Oct. 31, 2011 | Three Months<br>Ended<br>Oct. 31, 2010 |     | Three Months<br>Ended<br>Oct. 31, 2011 | Three Months<br>Ended<br>Oct. 31, 2010 |
|---|--|--|-----|--|--|
| <b>Nonderivatives<br/>designated as hedging<br/>relationships</b> |  |  |     |  |  |
| Net investment hedge  | \$ (1,849)                             | \$ (4,913)                             | N/A | \$ —                                   | \$ —                                   |

(a) There were no gains or losses recognized in earnings related to the ineffective portion of the hedging relationship or related to the amount excluded from the assessment of hedge effectiveness for the three months ended October 31, 2011 and October 31, 2010.

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

NOTE 14 - COMPREHENSIVE INCOME

|   | <b>Three Months</b>  |                      |
|---|----------------------|----------------------|
|   | <b>Oct. 31, 2011</b> | <b>Oct. 31, 2010</b> |
| Net earnings  | \$ 69,455            | \$ 69,455            |
| Unrealized translation adjustment                   | (24,934)             | (24,934)             |
| Income taxes  | 802                  | 802                  |
| Unrealized translation adjustment, net              | (24,132)             | (24,132)             |
| Pension liability adjustment                        | 6,254                | 6,254                |
| Income taxes  | (2,023)              | (2,023)              |
| Pension liability adjustment, net                   | 4,231                | 4,231                |
| Change in unrealized investment (losses)/gains      | (9,606)              | (9,606)              |
| Income taxes  | 3,458                | 3,458                |
| Change in unrealized investment (losses)/gains, net | (6,148)              | (6,148)              |
| Total comprehensive income                          | <u>\$ 43,406</u>     | <u>\$ 43,406</u>     |

Unrealized investment gains on available-for-sale securities, net of related income taxes, consist of the following:

|  | <b>Three Months</b>  |                      |
|--|----------------------|----------------------|
|  | <b>Oct. 31, 2011</b> | <b>Oct. 31, 2010</b> |
| Unrealized (losses)/gains arising during the period            | \$ (375)             | \$ (375)             |
| Income taxes   | (28)                 | (28)                 |
| Net unrealized (losses)/gains arising during the period        | (403)                | (403)                |
| Reclassification adjustment for gains included in net earnings | (5,745)              | (5,745)              |
| Change in unrealized investment (losses)/gains, net            | <u>\$ (6,148)</u>    | <u>\$ (6,148)</u>    |

NOTE 15 - SEGMENT INFORMATION

The Company's reportable segments, which are also its operating segments, consist of the Company's Life Sciences and Industrial businesses.

The following table presents sales and operating profit by segment reconciled to earnings before income taxes, for the three months ended October 31, 2011 and October 31, 2010.

|                          | <b>Three Months</b>  |                      |
|--------------------------|----------------------|----------------------|
|                          | <b>Oct. 31, 2011</b> | <b>Oct. 31, 2010</b> |
| <b>SALES:</b>            |                      |                      |
| Life Sciences            | \$ 356,133           | \$ 356,133           |
| Industrial               | 349,508              | 349,508              |
| Total                    | <u>\$ 705,641</u>    | <u>\$ 705,641</u>    |
| <b>SEGMENT PROFIT:</b>   |                      |                      |
| Life Sciences            | \$ 88,982            | \$ 88,982            |
| Industrial               | 48,141               | 48,141               |
| Total segment profit     | 137,123              | 137,123              |
| Corporate Services Group | 15,701               | 15,701               |

|                              |                  |           |
|------------------------------|------------------|-----------|
| Operating profit             | 121,422          |           |
| ROTC                         | 22,984           |           |
| Interest expense, net        | 5,945            |           |
| Earnings before income taxes | <u>\$ 92,493</u> | <u>\$</u> |

## **ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.**

### **Forward-Looking Statements and Risk Factors**

The following discussion should be read together with the accompanying condensed consolidated financial statements and notes thereto and other financial information in this Form 10-Q and in the Pall Corporation and its subsidiaries (hereinafter collectively called the "Company") Annual Report on Form 10-K for the fiscal year ended July 31, 2011 ("2011 Form 10-K"). The discussion under the subheading "Review of Operating Segments" below is in local currency (i.e., had exchange rates not changed year over year) unless otherwise indicated. Company management considers local currency change to be an important measure because by excluding the impact of volatility of exchange rates, underlying volume change is clearer. Dollar amounts discussed below are in thousands, unless otherwise indicated, except per share dollar amounts. In addition, per share dollar amounts are discussed on a diluted basis. The Company utilizes certain estimates and assumptions affecting the reported financial information as well as to quantify the impact of various significant factors that contribute to the changes in the Company's periodic results included in the discussion below.

The matters discussed in this Quarterly Report contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those that address activities, events or developments that the Company or management intends, expects, projects, believes or anticipates will or may occur in the future. All statements regarding future performance, earnings projections, earnings guidance, management's expectations about its future cash needs and effective tax rate, and other future events or developments are forward-looking statements. Forward-looking statements are those that use terms such as "may," "will," "expect," "believe," "intend," "should," "could," "anticipate," "estimate," "forecast," "project," "plan," "predict," "potential," and similar expressions. Forward-looking statements contained in this and other written and oral reports are based on management's assumptions and assessments in light of past experience and trends, current conditions, expected future developments and other relevant factors.

The Company's forward-looking statements are subject to risks and uncertainties and are not guarantees of future performance, and actual results, developments and business decisions may differ materially from those envisaged by the Company's forward-looking statements. Such risks and uncertainties include, but are not limited to, those discussed in Part I-Item 1A.-Risk Factors in the 2011 Form 10-K, and other reports the Company files with the Securities and Exchange Commission, including: the impact of legislative, regulatory and political developments globally; the impact of the uncertain global economic environment; the extent to which adverse economic conditions may affect our sales volume and results; changes in product mix, market mix and product pricing, particularly relating to the expansion of the systems business; demand for our products and business relationships with key customers and suppliers, which may be impacted by their cash flow and payment practices; delays or cancellations in shipments; our ability to develop and commercialize new technologies; our ability to obtain regulatory approval or market acceptance of new technologies; our ability to successfully complete our business improvement initiatives, which include supply chain enhancements and integrating and upgrading our information systems; the effect of a serious disruption in our information systems; fluctuations in our effective tax rate; volatility in foreign currency exchange rates, interest rates and energy costs and other macroeconomic challenges currently affecting us; increase in costs of manufacturing and operating costs; our ability to achieve and sustain the savings anticipated from cost reduction and gross margin improvement initiatives; our ability to attract and retain management talent, as well as the successful integration of the Company's new Chief Executive Officer and President; the impact of pricing and other actions by competitors; the effect of litigation and regulatory inquiries associated with the restatement of our prior period financial statements; the effect of the restrictive covenants in our debt facilities; our ability to enforce patents and protect proprietary products and manufacturing techniques; and our ability to successfully complete or integrate any acquisitions. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company makes these statements as of the date of this disclosure and undertakes no obligation to update them, whether as a result of new information, future developments or otherwise.

#### *Review of Consolidated Results*

Sales in the first quarter of fiscal year 2012 increased 16.5% to \$705,641 from \$605,477 in the first quarter of fiscal year 2011. Exchange rates used to translate foreign subsidiary results into U.S. Dollars increased reported sales by \$28,201, primarily due to the weakening of the U.S. Dollar against various Asian currencies (the Japanese Yen ("JPY"), Korean Won, Australian Dollar and Chinese Renminbi) and European currencies (the Euro and Swiss Franc). In local currency, sales increased 11.9%. Increased pricing contributed \$3,126 to overall sales in the quarter, primarily attributable to an improvement in Life Sciences.

Life Sciences segment sales increased 9.6% (in local currency) reflecting growth in all three of its markets, with sales in the BioPharmaceuticals market particularly strong. Industrial segment sales increased 14.3% (in local currency) reflecting strong growth in the Energy & Water and Aeropower markets. Sales in Microelectronics were down slightly (in local currency). Overall consumable filtration products (including appurtenant hardware sales) increased 8.8% (in local currency) reflecting growth of 7.5% in Life Sciences and 10.3% in Industrial. Overall systems sales increased 43.0% (in local currency) reflecting growth of over 40% in both the Life Sciences and Industrial segments. Systems sales represented 11.3% of total sales in the first quarter of fiscal year 2012 compared to 9.0% in the first quarter of fiscal year 2011. Sales in emerging markets grew about 35% in the quarter, and now represent about 20% of total sales. For a detailed discussion of sales, refer to the section "Review of Operating Segments" below.

Gross margin in the first quarter of fiscal year 2012 decreased 50 basis points to 50.5% from 51.0% in the first quarter of fiscal year 2011. This reflects an increase in gross margin in the Life Sciences segment of 130 basis points offset by a decrease in gross margin in the Industrial segment of 220 basis points. For a detailed discussion of the factors impacting gross margin by segment, refer to the section "Review of Operating Segments" below.

Selling, general and administrative ("SG&A") expenses in the first quarter of fiscal year 2012 increased by \$31,598, or 17.3% (an increase of \$24,164, or 13.3%, in local currency). This increase is reflected in both segments and the Corporate Services Group. Selling expenses in local currency increased approximately 13%, while general and administrative ("G&A") expenses increased about 15%. In addition to inflationary increases in payroll and related costs affecting both selling and G&A expenses, the overall increase in SG&A (in local currency) primarily reflects:

- increased selling expenses related to resource deployment related to organic geographic expansion in Latin America, Middle East and Asia, principally impacting both Industrial and Life Sciences,
- incremental costs (both selling and G&A) related to an acquisition in Brazil, impacting both segments, and
- investments in information technology.

As a percentage of sales, SG&A expenses were 30.3% compared to 30.1% in the first quarter of fiscal year 2011. SG&A expenses as a percentage of sales reflects the increase in spending in key areas as discussed above partly offset by the leverage of an increasing sales base. As a percentage of sales, selling expenses were 17.2% compared to 17.0% in the first quarter of fiscal year 2011. As a percentage of sales, G&A expenses were 13.1% on par with the first quarter of fiscal year 2011. For a detailed discussion of SG&A by business, refer to the section "Review of Operating Segments" below.

Research and development ("R&D") expenses were \$20,938 in the first quarter of fiscal year 2012 compared to \$20,169 in the first quarter of fiscal year 2011, an increase of \$769, or 3.8% (\$516, or 2.6% in local currency). The increase in R&D expenses in local currency reflects increased spending in the Industrial segment partly offset by a decline in Life Sciences. As a percentage of sales, R&D expenses were 3.0% compared to 3.3% in the first quarter of fiscal year 2011. For a detailed discussion of R&D by business, refer to the section "Review of Operating Segments" below.

In the first quarter of fiscal year 2012, the Company recorded restructuring and other charges ("ROTC") of \$22,984. ROTC in the quarter was primarily comprised of severance, professional fees and other costs related to the Company's cost reduction initiatives, primarily in the Industrial segment as well as charges related to certain employment contract obligations. In the first quarter of fiscal year 2011, the Company recorded ROTC of \$1,409, primarily comprised of professional fees and other costs related to the Company's cost reduction initiatives.

The details of ROTC for the three months ended October 31, 2011 and October 31, 2010 as well as the activity related to restructuring liabilities that were recorded in the three months ended October 31, 2011, and in fiscal years 2011, 2010 and 2009, can be found in Note 6, Restructuring and Other Charges, Net, to the accompanying condensed consolidated financial statements.

Earnings before interest and income taxes ("EBIT") were \$98,438 in the first quarter of fiscal year 2012, a decrease of 6.1% compared to \$104,797 in the first quarter of fiscal year 2011. The impact of foreign currency translation increased EBIT by approximately \$8,374, or 8% in the first quarter of fiscal year 2012. As a percentage of sales, EBIT were 14.0% compared to 17.3% in the first quarter of fiscal year 2011.



Net interest expense in the first quarter of fiscal year 2012 was \$5,945 compared to \$7,294 in the first quarter of fiscal year 2011. The decrease in net interest expense reflects a reduction in interest rates compared to the first quarter of fiscal year 2011 as a result of the Company's commercial paper program that was established in the second quarter of fiscal year 2011, as well as an increase in interest income.

In the first quarter of fiscal year 2012, the Company's effective tax rate was 24.9% as compared to 26.8% in the first quarter of fiscal year 2011. Excluding the impacts of ROTC discussed above, the effective tax rate for the first quarter of fiscal year 2012 would have been 24.5%. This decrease reflects tax benefits associated with the establishment of the Company's Asian headquarters in Singapore and the expansion of the Company's European headquarters. The Company expects its effective tax rate for the full fiscal year 2012 to be approximately 24.5%, exclusive of the impact of ROTC and discrete items in future periods. The actual effective tax rate for the full fiscal year 2012 may differ materially based on several factors, including the geographical mix of earnings in tax jurisdictions, enacted tax laws, the resolution of tax audits, the timing and amount of foreign dividends, state and local taxes, the ratio of permanent items to pretax book income, and the implementation of various global tax strategies as well as other factors.

Net earnings in the first quarter of fiscal year 2012 were \$69,455, or 59 cents per share, compared with net earnings of \$71,409, or 61 cents in the first quarter of fiscal year 2011. Company management estimates that foreign currency translation increased earnings per share by 5 cents in the first quarter of fiscal year 2012.

#### Review of Operating Segments

The following table presents sales and segment profit by business segment, reconciled to earnings before income taxes, for the three months ended October 31, 2011 and October 31, 2010.

|                              | Oct. 31, 2011     | %      | Oct. 31, 2010     | %      | %      |
|------------------------------|-------------------|--------|-------------------|--------|--------|
|                              |                   | Margin |                   | Margin | Change |
| <b>SALES:</b>                |                   |        |                   |        |        |
| Life Sciences                | \$ 356,133        |        | \$ 311,580        |        | 14.3   |
| Industrial                   | 349,508           |        | 293,897           |        | 18.9   |
| Total                        | <u>\$ 705,641</u> |        | <u>\$ 605,477</u> |        | 16.5   |
| <b>SEGMENT PROFIT :</b>      |                   |        |                   |        |        |
| Life Sciences                | \$ 88,982         | 25.0   | \$ 73,188         | 23.5   | 21.6   |
| Industrial                   | 48,141            | 13.8   | 45,339            | 15.4   | 6.2    |
| Total segment profit         | 137,123           | 19.4   | 118,527           | 19.6   | 15.7   |
| Corporate Services Group     | 15,701            |        | 12,321            |        | 27.4   |
| Operating profit             | 121,422           | 17.2   | 106,206           | 17.5   | 14.3   |
| ROTC, net                    | 22,984            |        | 1,409             |        |        |
| Interest expense, net        | 5,945             |        | 7,294             |        |        |
| Earnings before income taxes | <u>\$ 92,493</u>  |        | <u>\$ 97,503</u>  |        |        |

#### Life Sciences:

Presented below are Summary Statements of Segment Profit for the Life Sciences segment for the three months ended October 31, 2011 and October 31, 2010:

|                | Oct. 31, 2011    | % of  | Oct. 31, 2010    | % of  | %      |
|----------------|------------------|-------|------------------|-------|--------|
|                |                  | Sales |                  | Sales | Change |
| Sales          | \$ 356,133       |       | \$ 311,580       |       | 14.3   |
| Cost of sales  | 157,250          | 44.2  | 141,661          | 45.5  | 11.0   |
| Gross margin   | 198,883          | 55.8  | 169,919          | 54.5  | 17.0   |
| SG&A           | 96,596           | 27.1  | 83,474           | 26.8  | 15.7   |
| R&D            | 13,305           | 3.7   | 13,257           | 4.3   | 0.4    |
| Segment profit | <u>\$ 88,982</u> | 25.0  | <u>\$ 73,188</u> | 23.5  | 21.6   |

The tables below present sales by market and Region within the Life Sciences segment for the three months ended October 31, 2011 and October 31, 2010, including the effect of exchange rates for comparative purposes.

|                            | Oct. 31, 2011     | Oct. 31, 2010     | %<br>Change | Exchange<br>Rate<br>Impact | %<br>Change in<br>Local<br>Currency |
|----------------------------|-------------------|-------------------|-------------|----------------------------|-------------------------------------|
| <b>By Market</b>           |                   |                   |             |                            |                                     |
| BioPharmaceuticals         | \$ 196,012        | \$ 161,409        | 21.4        | \$ 9,041                   | 15.8                                |
| Medical                    | 104,102           | 98,542            | 5.6         | 3,062                      | 2.5                                 |
| Food & Beverage            | 56,019            | 51,629            | 8.5         | 2,396                      | 3.9                                 |
| <b>Total Life Sciences</b> | <b>\$ 356,133</b> | <b>\$ 311,580</b> | <b>14.3</b> | <b>\$ 14,499</b>           | <b>9.6</b>                          |
| <b>By Region</b>           |                   |                   |             |                            |                                     |
| Americas (a)               | \$ 124,319        | \$ 109,651        | 13.4        | \$ 223                     | 13.2                                |
| Europe                     | 167,190           | 145,388           | 15.0        | 9,744                      | 8.3                                 |
| Asia                       | 64,624            | 56,541            | 14.3        | 4,532                      | 6.3                                 |
| <b>Total Life Sciences</b> | <b>\$ 356,133</b> | <b>\$ 311,580</b> | <b>14.3</b> | <b>\$ 14,499</b>           | <b>9.6</b>                          |

(a) Formerly Western Hemisphere.

Life Sciences segment sales increased 9.6% in the first quarter of fiscal year 2012 compared to the first quarter of fiscal year 2011. The increase in sales reflects growth in consumables and systems sales of 7.5% and 49.5%, respectively. Sales in emerging markets grew about 22% while sales in active markets grew about 8%.

Increased pricing (primarily in the BioPharmaceuticals market) contributed \$2,612, or about 1%, to consumables sales growth in the quarter and the volume related consumables sales increase was about 6.5%. Systems sales represented 6.7% of total Life Sciences sales in the quarter compared to 5.0% in the first quarter of fiscal year 2011. Life Sciences sales represented approximately 50% of total Company sales in the quarter compared to 51%, in the first quarter of fiscal year 2011.

Sales in the BioPharmaceuticals market, which is comprised of two submarket groupings (Pharmaceuticals and Laboratory), and represented 55% of total Life Sciences sales, increased 15.8%. The sales results by the submarkets that comprise BioPharmaceuticals are discussed below:

- Sales in the Pharmaceuticals submarket, which represented about 45% of total Life Sciences sales, increased 16.8% compared to the first quarter of fiscal year 2011 driven by growth in all three Regions. Consumables sales increased 16.1%, while systems sales grew 24.9%. Continued strength in the biotech sector (in all Regions) as well as in plasma were key growth drivers. Increased demand for the Company's single-use products also contributed to the growth in the quarter.
- Sales in the Laboratory submarket, which represented less than 10% of Life Sciences sales, grew 10.8%, with all Regions contributing. The growth in this submarket reflects end-user demand for products used in research and quality control fueled by underlying growth in the pharmaceutical marketplace. Emerging markets in Latin America and Asia, particularly China and India, also contributed to the growth compared to the first quarter of last year.

Sales in the Medical market, which is comprised of blood filtration product sales and other infection and patient protection products sold to hospitals, original equipment manufacturers ("OEM") and cell therapy developers, represented close to 30% of total Life Sciences sales, increased 2.5% compared to the first quarter of fiscal year 2011.

- Sales of blood filtration products, which represented approximately 15% of total Life Sciences sales, increased 3.5%. The growth in the quarter reflects increased sales in the Americas, the Company's largest blood filtration Region, and Asia, partly offset by a decline in Europe. The growth in blood filtration sales in the Americas was driven by the U.S. and reflects new product conversions at certain customers. The growth in Asia, the Company's smallest blood filtration Region, reflects increased sales in several countries. The decline in sales in Europe reflects the impact of economic conditions in the Region.
- OEM sales, which represented less than 10% of total Life Sciences sales, grew 3.5% primarily driven by increased intravenous filter ("IV") sales in the Americas driven by regulatory requirements in the U.S.
- Sales to Hospitals, which represented less than 10% of total Life Sciences sales, were flat in the quarter reflecting timing of shipments.

Sales in the Food & Beverage market, which represented about 16% of total Life Sciences sales, increased 3.9%. Systems sales almost doubled, while consumables sales declined 6.9%. By Region, the increase in sales in the quarter reflects growth in the Americas and Asia, partly offset by a decline in Europe. Sales in the Americas and Asia were up driven by new market applications and products in food contact compliance and beer stabilization, augmented by growth in emerging markets. Sales in Europe were down reflecting decreased production volume in the alcoholic beverage sectors and the impact of the divestiture of a non-core asset group in Italy, which hampered consumables sales growth.

Life Sciences gross margin in the first quarter of fiscal year 2012 increased 130 basis points to 55.8% from 54.5% in the first quarter of fiscal year 2011. The increase in gross margin in the quarter reflects manufacturing cost savings and the benefit of exchange rates on foreign currency denominated sourced goods primarily in the Euro-zone, which in the aggregate outpaced inflation.

SG&A expenses in the first quarter of fiscal year 2012, increased by \$13,122, or 15.7% (an increase of \$9,687, or 11.6% in local currency) compared to the first quarter of fiscal year 2011. Selling expenses in local currency increased close to 13%, while G&A expenses increased about 10%. In addition to inflation in payroll and related costs that impacted both selling and G&A expenses, the increase in SG&A (in local currency) principally reflects increased spending related to regional expansion in emerging markets (impacting selling and G&A expenses), including the Latin America acquisition, and investments in information technology as discussed in the Review of Consolidated Results above. SG&A as a percentage of sales increased to 27.1% from 26.8% in the first quarter of fiscal year 2011. The increase in SG&A as a percentage of sales reflects the increase in spending in key areas as discussed above, partly offset by the leverage of sales growth. As a percentage of sales, selling expenses were 16.4% compared to 15.9% in the first quarter of fiscal year 2011. As a percentage of sales, G&A expenses were 10.7% compared to 10.9% in the first quarter of fiscal year 2011.

R&D expenses in the first quarter of fiscal year 2012 were \$13,305, an increase of \$48, or less than 1% (a decrease of \$139, or 1.0% in local currency). As a percentage of sales, R&D expenses were 3.7% compared to 4.3% in the first quarter of fiscal year 2011.

Segment profit dollars were \$88,982, an increase of \$15,794, or 21.6% (\$10,098, or 13.8% in local currency) compared to the first quarter of fiscal year 2011. Segment margin improved to 25.0% from 23.5% in the first quarter of fiscal year 2011.

#### Industrial:

Presented below are summary Statements of Segment Profit for the Industrial segment for the three months ended October 31, 2011 and October 31, 2010:

|                | Oct. 31, 2011 | % of Sales | Oct. 31, 2010 | % of Sales | % Change |
|----------------|---------------|------------|---------------|------------|----------|
| Sales          | \$ 349,508    |            | \$ 293,897    |            | 18.9     |
| Cost of sales  | 192,135       | 55.0       | 155,143       | 52.8       | 23.8     |
| Gross margin   | 157,373       | 45.0       | 138,754       | 47.2       | 13.4     |
| SG&A           | 101,599       | 29.1       | 86,503        | 29.4       | 17.5     |
| R&D            | 7,633         | 2.2        | 6,912         | 2.4        | 10.4     |
| Segment profit | \$ 48,141     | 13.8       | \$ 45,339     | 15.4       | 6.2      |

The tables below present sales by market and Region within the Industrial segment for the three months ended October 31, 2011 and October 31, 2010, including the effect of exchange rates for comparative purposes.

|                  | Oct. 31, 2011 | Oct. 31, 2010 | % Change | Exchange Rate Impact | % Change in Local Currency |
|------------------|---------------|---------------|----------|----------------------|----------------------------|
| <b>By Market</b> |               |               |          |                      |                            |
| Energy & Water   | \$ 137,218    | \$ 102,393    | 34.0     | \$ 4,718             | 29.4                       |
| Aeropower        | 133,700       | 116,549       | 14.7     | 4,031                | 11.3                       |
| Microelectronics | 78,590        | 74,955        | 4.9      | 4,953                | (1.8)                      |
| Total Industrial | \$ 349,508    | \$ 293,897    | 18.9     | \$ 13,702            | 14.3                       |
| <b>By Region</b> |               |               |          |                      |                            |
| Americas (a)     | \$ 109,065    | \$ 100,468    | 8.6      | \$ 296               | 8.3                        |
| Europe           | 99,113        | 81,681        | 21.3     | 3,931                | 16.5                       |
| Asia             | 141,330       | 111,748       | 26.5     | 9,475                | 18.0                       |
| Total Industrial | \$ 349,508    | \$ 293,897    | 18.9     | \$ 13,702            | 14.3                       |

(a) Formerly Western Hemisphere.

---

Industrial segment sales increased 14.3%, reflecting strong growth in the Energy & Water and Aeropower markets, partly offset by a decline in the Microelectronics market. The increase in sales in the quarter reflects growth in consumables and systems sales of 10.3% and 40.3%, respectively. Sales in emerging markets increased about 46%, while sales in mature markets grew 7%.

Increased pricing contributed \$514, or less than 0.5%, to consumables sales growth in the quarter. Systems sales represented 16.0% of total Industrial sales in the quarter compared to 13.1% in the first quarter of fiscal year 2011. Industrial sales represented approximately 50.0% of total Company sales in the quarter compared to 49.0% in the first quarter of fiscal year 2011.

Sales in the Energy & Water market, which is comprised of three submarkets; Fuels & Chemicals, Power Generation and Municipal Water, and represented about 39% of total Industrial sales, increased 29.4%. The sales results by submarket are discussed below:

- Sales in the Fuels & Chemicals submarket, which represented approximately 20% of total Industrial sales increased 35.8% reflecting double-digit growth in all Regions. Consumables sales increased 17.7%, while systems sales grew over 150%. Growth in emerging markets was a key growth driver in the quarter. Furthermore, all sectors of the market contributed with oil & gas, refining and alternative energy experiencing particularly robust growth.
- Sales in the Power Generation submarket, which represented approximately 10% of total Industrial sales, increased 16.6% primarily driven by strong growth in the nuclear and wind-turbine sectors. Increased sales in the turbine OEM and fossil fuel sectors also contributed to the growth in the quarter. By Region, the sales results in the quarter reflect strong growth in Asia and Europe. Sales in the Americas were down as growth in consumables sales were offset by a decline in systems sales.
- Municipal Water submarket sales, which represented less than 10% of total Industrial sales, increased 29.0%. By Region, sales in the Americas (the Company's largest Municipal Water Region) grew 13.5%, as U.S. municipalities continue to invest in membrane filtration to comply with drinking water regulations. Sales in Europe decreased 11.8% reflecting a reduction in capital spending primarily in the landfill leachate sector due to economic conditions in the Region. In Asia, the Company's smallest Municipal Water Region, sales increased over 300% driven by a large wastewater project in Australia.

The Aeropower market is comprised of sales of air, water, lubrication, fuel and machinery and hydraulic protection products to OEM and end-user customers in Military and Commercial Aerospace as well as in the Machinery & Equipment submarkets, which consist of a grouping of producers of mobile equipment and trucks, pulp and paper, mining equipment, automotive products and metals. Sales in the Aeropower market, which represented about 38% of total Industrial sales, increased 11.3%. The sales results by the submarkets that comprise Aeropower are discussed below:

- Sales in the Machinery & Equipment submarket, which represented approximately 20% of total Industrial sales, increased 12.3%, with all Regions contributing to the growth. The increase in Machinery & Equipment sales was driven by growth in the mining and mobile OEM sectors. Growth in emerging markets was also a key growth driver in the quarter.
- Sales to the Military Aerospace submarket, which represented less than 10% of total Industrial sales, increased 5.7% primarily driven by CH-47 helicopter program sales in the Americas.
- Sales to the Commercial Aerospace submarket, which represented less than 10% of total Industrial sales, increased 14.5%, with all Regions contributing to the growth. The growth in Commercial Aerospace sales was primarily driven by an increase in OEM production rates, and an increase in aftermarket sales related to an increase in air miles flown.

Microelectronics sales, which represented about 23% of total Industrial sales, decreased 1.8% reflecting a decline in semiconductor chip production, weakness in the display market and decreased OEM demand. Sales in Asia, the Company's largest Microelectronics Region, were flat. The Americas, which generates the largest share of the Company's OEM sales, declined 14.5%. Sales in Europe, the Company's smallest Microelectronics Region, grew 10%, benefiting from capital goods sales in the semiconductor sector.

Industrial gross margin decreased 220 basis points to 45.0% from 47.2% in the first quarter of fiscal year 2011. The decrease in gross margin reflects unfavorable mix primarily due to the negative impact from an increase in systems sales, as discussed above, which typically have lower gross margins than consumables, and a reduction in consumables product sales in the Microelectronics market.

SG&A expenses increased by \$15,096, or 17.5% (an increase of \$11,148, or 12.9% in local currency) compared to the first quarter of fiscal year 2011. Selling expenses in local currency increased about 12%, while G&A expenses were up about 14%. In addition to inflation in payroll and related costs, the increase in SG&A (in local currency) principally reflects increased spending related to regional expansion in emerging markets (impacting selling and G&A expenses), including the Latin America acquisition, and investments in information technology as discussed in the Review of Consolidated Results, as well as costs related to bringing Industrial into the European and Asian headquarters. SG&A expenses as a percentage of sales decreased to 29.1% from 29.4% in the first quarter of fiscal year 2011. The decrease in SG&A as a percentage of sales reflects the leverage of the increase in sales, partly offset by the increase in spending in key areas as discussed above. As a percentage of sales, selling expenses were 17.7% compared to 18.0% in the first quarter of fiscal year 2011. As a percentage of sales, G&A expenses were 11.4% compared to 11.5% in the first quarter of fiscal year 2011.

R&D expenses were \$7,633 in the first quarter of fiscal year 2012 compared to \$6,912 in the first quarter of fiscal year 2011, an increase of \$721, or 10.4% (\$655, or 9.5% in local currency). As a percentage of sales, R&D expenses were 2.2% compared to 2.4% in the first quarter of fiscal year 2011.

Segment profit dollars in the first quarter of fiscal year 2012 were \$48,141, an increase of \$2,802, or 6.2%. In local currency segment profit was essentially flat compared to the first quarter of fiscal year 2011. Segment margin decreased to 13.8% from 15.4% in the first quarter of fiscal year 2011.

#### **Corporate Services Group:**

Corporate Services Group expenses in the first quarter of fiscal year 2012 were \$15,701 compared to \$12,321 in the first quarter of fiscal year 2011, an increase of \$3,380 or 27.4% (\$3,329 or 27.0% in local currency). The increase in Corporate Services Group expenses primarily reflects an increase in payroll and related costs and the costs associated with the executive management transition.

#### **Liquidity and Capital Resources**

Non-cash working capital, which is defined as working capital excluding cash and cash equivalents, notes receivable, notes payable and the current portion of long-term debt, was approximately \$714,800 at October 31, 2011 as compared with \$676,500 at July 31, 2011. Excluding the effect of foreign exchange (discussed below), non-cash working capital increased approximately \$48,300 compared to July 31, 2011.

The Company's balance sheet is affected by spot exchange rates used to translate local currency amounts into U.S. Dollars. In comparing spot exchange rates at October 31, 2011 to those at July 31, 2011, the Euro and the British Pound have weakened against the U.S. Dollar, while the JPY has strengthened against the U.S. Dollar. The effect of foreign currency translation decreased non-cash working capital by \$9,963, including net inventory, net accounts receivable and other current assets by \$4,907, \$8,695 and \$2,179, respectively, as compared to July 31, 2011. Additionally, foreign currency translation decreased accounts payable and other current liabilities by \$5,543 and current income taxes payable by \$275.

Net cash provided by operating activities in the first quarter of fiscal year 2012 was \$78,356 as compared to \$58,686 in the first quarter of fiscal year 2011, an increase of \$19,670, or about 34% reflecting the increase in net earnings exclusive of ROTC, which did not have a material impact on cash outflows accompanied by an improvement in working capital management.

The Company's full cash conversion cycle, defined as days in inventory outstanding ("DIO") plus days sales outstanding ("DSO") less days payable outstanding ("DPO"), decreased to 130 days in the quarter ended October 31, 2011 from 142 days in the quarter ended October 31, 2010. This improvement reflects a decrease in DSO and DIO partly offset by a decrease in DPO.

Free cash flow, which is defined as net cash provided by operating activities less capital expenditures, was \$21,707, or about 31% of net earnings in the first quarter of fiscal year 2012, as compared with \$33,328, or about 47% of net earnings in the first quarter of fiscal year 2011. The decrease in free cash flow reflects an increase in capital expenditures principally related to the purchase of a new facility in Europe. The Company utilizes free cash flow as one way to measure its current and future financial performance. Company management believes this measure is important because it is a key element of its planning. The following table reconciles net cash provided by operating activities to free cash flow.

|   | <b>Oct. 31, 2011</b> | <b>Oct. 31, 2010</b> |
|---|----------------------|----------------------|
| Net cash provided by operating activities | \$ 78,356            | \$ 58,686            |
| Less capital expenditures                 | 56,649               | 25,358               |
| Free cash flow                            | <u>\$ 21,707</u>     | <u>\$ 33,328</u>     |
| Net Earnings                              | \$ 69,455            | \$ 71,409            |
| Free cash flow conversion                 | 31.3%                | 46.7%                |

Overall, net debt (debt net of cash and cash equivalents) as a percentage of total capitalization (net debt plus equity) was 9.7% at October 31, 2011 as compared to 9.1% at July 31, 2011. Net debt increased by approximately \$15,100 compared with July 31, 2011, reflecting a decrease in cash and cash equivalents of \$72,300 partly offset by a decline in gross debt of \$70,100. The impact of foreign exchange rates increased net debt by about \$12,900.

The Company's 5-year senior revolving credit facility contains financial covenants which require the Company to maintain a minimum consolidated net interest coverage ratio of 3.5:1, based upon trailing four quarters results, and a maximum consolidated leverage ratio of 3.5:1, based upon trailing four quarters results. In addition, the facility includes other covenants that under certain circumstances can restrict the Company's ability to incur additional indebtedness, make investments and other restricted payments, enter into sale and leaseback transactions, create liens and sell assets. As of October 31, 2011, the Company was in compliance with all related financial and other restrictive covenants, including limitations on indebtedness.

The Company manages certain financial exposures through a risk management program that includes the use of foreign exchange and interest rate derivative financial instruments. Derivatives are executed with counterparties with a minimum credit rating of "A" by Standard and Poor's and Moody's Investor Services, in accordance with the Company's policies. The Company does not utilize derivative instruments for trading or speculative purposes.

The Company conducts transactions in currencies other than their functional currency. These transactions include non-functional currency intercompany and external sales as well as intercompany and external purchases. The Company uses foreign exchange forward contracts, matching the notional amounts and durations of the receivables and payables resulting from the aforementioned underlying foreign currency transactions, to mitigate the exposure to earnings and cash flows caused by changing foreign exchange rates. The risk management objective of holding foreign exchange derivatives is to mitigate volatility to earnings and cash flows due to changes in foreign exchange rates.

The notional amount of foreign currency forward contracts entered into during the three months ended October 31, 2011 was \$882,544. The notional amount of foreign currency forward contracts outstanding as of October 31, 2011 was \$278,695. The Company's foreign currency balance sheet exposures resulted in the recognition of a loss within SG&A of approximately \$2,586 in the three months ended October 31, 2011, before the impact of the measures described above. Including the impact of the Company's foreign exchange derivative instruments, the net recognition within SG&A was a loss of approximately \$1,171 in the three months ended October 31, 2011.

As of October 31, 2011, the Company had \$145,000 of outstanding commercial paper, all of which is recorded as current liabilities under notes payable in the Company's consolidated balance sheet. Commercial paper issuances during the quarter carried interest rates ranging between 0.37% and 0.42% and original maturities between 29 and 62 days. As of October 31, 2011, the Company does not have any outstanding borrowings under its existing senior revolving credit facility.

The Company utilizes cash flow generated from operations and its senior revolving credit facility to meet its short-term liquidity needs. Company management considers its cash balances, lines of credit and access to the commercial paper and other credit markets, along with the cash typically generated from operations, to be sufficient to meet its anticipated liquidity needs.

As of October 31, 2011, the amount of cash and cash equivalents held by foreign subsidiaries was \$451,757. The Company does not expect any restrictions or taxes on repatriation of cash held outside of the U.S. to have a material effect on the Company's overall liquidity or financial position.

Capital expenditures were \$56,649 in the first quarter of fiscal year 2012. Depreciation expense was \$22,343 and amortization expense was \$4,192 in the first quarter of fiscal year 2012.

On October 16, 2008, the board authorized an expenditure of \$350,000 to repurchase shares. At July 31, 2011, there was \$203,037 remaining under this stock repurchase authorization. On September 26, 2011, the board authorized an expenditure of \$250,000 to repurchase shares. The Company did not repurchase stock in the first quarter of fiscal year 2012 leaving \$453,037 remaining at October 31, 2011 under the current stock repurchase programs. Net proceeds from stock plans were \$9,759 in the first quarter of fiscal year 2012.

In the first quarter of fiscal year 2012, the Company paid dividends of \$20,125 compared to \$36,976 in the first quarter of fiscal year 2011 reflecting the timing of dividend payments. The Company increased its quarterly dividend by 9.4% from 16 cents to 17.5 cents per share, effective with the dividend.

#### **Recently Issued Accounting Pronouncements**

In September 2011, the Financial Accounting Standards Board ("FASB") issued new accounting guidance intended to simplify goodwill impairment testing. Entities will be allowed to perform a qualitative assessment on goodwill impairment to determine whether it is more likely than not (defined as having a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. This guidance is effective for goodwill impairment tests performed in interim and annual periods for fiscal years beginning after December 15, 2011, which for the Company is the first quarter of fiscal 2013, with early adoption permitted. The Company does not expect this guidance will have a material impact on its results of operations or financial position.

In June 2011, the FASB issued new guidance on the presentation of comprehensive income. Specifically, the new guidance allows an entity to present components of net income and other comprehensive income in one continuous statement, referred to as the statement of comprehensive income, or in two separate, but consecutive statements. The new guidance eliminates the current option to report other comprehensive income and its components in the statement of changes in equity. While the new guidance changes the presentation of comprehensive income, there are no changes to the components that are recognized in net income or other comprehensive income under current accounting guidance. The adoption of this disclosure-only guidance will not have an impact on the Company's consolidated financial results and is effective for the Company beginning with its third quarter of fiscal year 2012.



In May 2011, the FASB issued amendments to fair value measurement and disclosure requirements. This guidance amends United States generally accepted accounting principles ("U.S. GAAP") to conform with measurement and disclosure requirements in International Financial Reporting Standards ("IFRS"). The amendments change the wording used to describe the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. This includes clarification of the Board's intent about the application of existing fair value measurement and disclosure requirements and those that change a particular principle or requirement for measuring fair value or for disclosing information about fair value measurements. In addition, to improve consistency in application across jurisdictions, some changes in wording are necessary to ensure that U.S. GAAP and IFRS fair value measurement and disclosure requirements are described in the same way (for example, using the word "shall" rather than "should" to describe the requirements in U.S. GAAP). This amended guidance is to be applied prospectively and is effective for the Company beginning with its third quarter of fiscal year 2012. The Company is currently evaluating this guidance and has not yet determined the impact the adoption will have on its consolidated financial statements.

### **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.**

There is no material change in the market risk information disclosed in Item 7A of the 2011 Form 10-K.

### **ITEM 4. CONTROLS AND PROCEDURES.**

There are a number of significant business improvement initiatives designed to improve processes and enhance customer and supplier relationships and opportunities. These include information systems upgrades and integrations that are in various phases of planning or implementation and contemplate enhancements of ongoing activities to support the growth of the Company's financial shared service capabilities and standardization of its financial systems. When taken together, these changes, which will occur over a multi year period, are expected to have a favorable impact on the Company's internal control over financial reporting. The Company is employing a project management and phased implementation approach that will provide continued monitoring and assessment in order to maintain the effectiveness of internal control over financial reporting during and subsequent to implementation of these initiatives.

In connection with the aforementioned business improvement initiatives, during fiscal years 2010 and 2011, certain significant operations migrated and are expected to continue to migrate in future fiscal quarters to the Company's global enterprise resource planning ("ERP") software system. The purpose of the ERP system is to facilitate (i) the flow of information between all business functions inside the boundaries of the Company and (ii) the management of the connections to outside stakeholders. Built on a centralized database and utilizing a common computing platform, the ERP system consolidates business operations into a more uniform, enterprise wide system environment. The Company's ERP implementation is accompanied by process changes and improvements, including those that impact internal control over financial reporting. No operations were migrated to the ERP system during the first quarter of fiscal year 2012.

There have been no changes in, including in connection with the above described initiative, the Company's internal control over financial reporting during the first quarter of fiscal year 2012 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's chief executive officer and chief financial officer, of the effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended. Based on this evaluation, the chief executive officer and chief financial officer concluded that the Company's disclosure controls and procedures are effective.

Any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

## **PART II. OTHER INFORMATION**

### **ITEM 1. LEGAL PROCEEDINGS.**

**(In thousands)**

As previously disclosed in the 2011 Form 10-K, the Company is subject to various regulatory proceedings and litigation, including with respect to various environmental matters. Reference is also made to Note 5, Contingencies and Commitments, to the accompanying condensed consolidated financial statements.

#### **Environmental Matters:**

The Company's condensed consolidated balance sheet at October 31, 2011 includes liabilities for environmental matters of approximately \$14,472, which relate primarily to the environmental proceedings discussed in the 2011 Form 10-K. In the opinion of management, the Company is in substantial compliance with applicable environmental laws and its current accruals for environmental remediation are adequate. However, as regulatory standards under environmental laws are becoming increasingly stringent, there can be no assurance that future developments, additional information and experience gained will not cause the Company to incur material environmental liabilities or costs beyond those accrued in its condensed consolidated financial statements.

### **ITEM 1A. RISK FACTORS.**

There is no material change in the risk factors reported in Item 1A of the 2011 Form 10-K. This report contains certain forward-looking statements that reflect management's expectations regarding future events and operating performance and speak only as of the date hereof. These statements are subject to risks and uncertainties, which could cause actual results to differ materially. For a description of these risks see "Management's Discussion and Analysis of Financial Condition and Results of Operations – Forward-Looking Statements and Risk Factors."

### **ITEM 6. EXHIBITS.**

See the Exhibit Index for a list of exhibits filed herewith or incorporated by reference herein.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Pall Corporation

December 9, 2011

/s/ LISA MCDERMOTT

Lisa McDermott  
Chief Financial Officer  
and Treasurer

/s/FRANCIS MOSCHELLA

Francis Moschella  
Vice President – Corporate Controller  
Chief Accounting Officer

## EXHIBIT INDEX

### Exhibit

### Number Description of Exhibit

|   |   |
|---|---|
| 3 | Restated Certificate of Incorporation of the Registrant as amended through September 1, 2010, filed as Exhibit 3.1(i) to the Registrant's Annual Report on Form 10-K for the fiscal year ended July 31, 2010. |
| 3 | By-Laws of the Registrant as amended through March 16, 2011, filed as Exhibit 3(ii) to the Registrant's Form 8-K filed on March 22, 2011.   |
| 3 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.   |
| 3 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.   |
| 3 | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.   |
| 3 | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.   |
| 1 | XBRL Instance Document**  |
| 1 | XBRL Taxonomy Extension Schema Document**   |
| 1 | XBRL Taxonomy Extension Calculation Linkbase Document**   |
| 1 | XBRL Taxonomy Extension Label Linkbase Document**   |
| 1 | XBRL Taxonomy Extension Presentation Linkbase Document**  |
| 1 | XBRL Taxonomy Extension Definition Linkbase Document**  |

\* Incorporated herein by reference.

† Exhibit filed herewith.

\*\* Users of this data are advised pursuant to Rule 406T of Regulation S-T that this interactive data file is deemed not filed or part of a registration statement or prospectus for the purposes of section 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities and Exchanges Act of 1934, as amended, and otherwise is not subject to liability under these sections.

**CHIEF EXECUTIVE OFFICER CERTIFICATION PURSUANT TO SECTION 302 OF  
THE SARBANES-OXLEY ACT OF 2002**

I, Lawrence D. Kingsley, certify that:

1. I have reviewed this report on Form 10-Q of Pall Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: December 9, 2011

/s/LAWRENCE D. KINGSLEY

---

Lawrence D. Kingsley

Chief Executive Officer and President

---

**CHIEF FINANCIAL OFFICER CERTIFICATION PURSUANT TO SECTION 302 OF  
THE SARBANES-OXLEY ACT OF 2002**

I, Lisa McDermott, certify that:

1. I have reviewed this report on Form 10-Q of Pall Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: December 9, 2011

/s/LISA MCDERMOTT

---

Lisa McDermott

Chief Financial Officer and Treasurer

---



**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350  
As Adopted Pursuant to  
Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of Pall Corporation (the "Company") on Form 10-Q for the quarterly period ending October 31, 2011, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Lawrence D. Kingsley, Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to my knowledge:

- (i) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

December 9, 2011

/s/LAWRENCE D. KINGSLEY

---

Lawrence D. Kingsley

Chief Executive Officer and President

---

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350  
As Adopted Pursuant to  
Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of Pall Corporation (the "Company") on Form 10-Q for the quarterly period ending October 31, 2011, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Lisa McDermott, Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to my knowledge:

- (i) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

December 9, 2011

/s/LISA MCDERMOTT

---

Lisa McDermott

Chief Financial Officer and Treasurer

---